Emerging concepts and directed therapeutics for the management of asthma: regulating the regulators

Autor: Shastri, MD, Chong, WC, Dua, K, Peterson, GM, Patel, RP, Mahmood, MQ, Tambuwala, M, Chellappan, DK, Hansbro, NG, Shukla, SD, Hansbro, PM

Asthma is a common, heterogeneous and serious disease, its prevalence has steadily risen in most parts of the world, and the condition is often inadequately controlled in many patients. Hence, there is a major need for new therapeutic approaches. Mil

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______363::e1e451017f66c8a2aa23b26b2b58bafd
https://hdl.handle.net/10453/144196

Fluorine-free superhydrophobic cotton fabric for highly-efficient gravity-driven oil/water separation

Autor: Voo, WX, Chong, WC, Teoh, HC, Mohammad, AW

Publikováno v: IOP Conference Series: Materials Science and Engineering; October 2022, Vol. 1257 Issue: 1 p012048-012048, 1p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Development of an hollow fiber solid phase microextraction method for the analysis of unbound fraction of imatinib and N-desmethyl imatinib in human plasma.

Autor: Dong WC; The School of Medicine, Nankai University, Tianjin 300071, China; Department of Pharmacy, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei Province 050051, China., Song MY; School of Pharmacy, Hebei Medical University, Shijiazhuang, Hebei Province 050017, China., Zheng TL; Department of Pharmacy, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei Province 050051, China., Zhang ZQ; Department of Pharmacy, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei Province 050051, China., Jiang Y; School of Pharmacy, Hebei Medical University, Shijiazhuang, Hebei Province 050017, China; Hebei Key Laboratory of Forensic Medicine, Shijiazhuang, Hebei Province 050017, China. Electronic address: jiangye@hebmu.edu.cn., Guo JL; Department of Orthopaedics, Hebei Medical University Third Hospital, Shijiazhuang, Hebei Province 050000, China. Electronic address: drjlguo@hebmu.edu.cn., Zhang YZ; The School of Medicine, Nankai University, Tianjin 300071, China; Department of Orthopaedics, Hebei Medical University Third Hospital, Shijiazhuang, Hebei Province 050000, China. Electronic address: yzzhang@hebmu.edu.cn.

Publikováno v: Journal of pharmaceutical and biomedical analysis [J Pharm Biomed Anal] 2024 Nov 15; Vol. 250, pp. 116405. Date of Electronic Publication: 2024 Aug 08.

Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC.

Autor: Saw SPL; Division of Medical Oncology, National Cancer Centre Singapore, Singapore; Duke-NUS Medical School, National University of Singapore, Singapore. Electronic address: stephanie.saw.p.l@singhealth.com.sg., Low YF; Division of Medical Oncology, National Cancer Centre Singapore, Singapore., Lai GGY; Division of Medical Oncology, National Cancer Centre Singapore, Singapore; Duke-NUS Medical School, National University of Singapore, Singapore., Chan LL; Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China., Wong WKY; Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, China., Tsui G; Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, China., Chen OH; Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, China., Seet AOL; Division of Medical Oncology, National Cancer Centre Singapore, Singapore; Duke-NUS Medical School, National University of Singapore, Singapore., Tan WC; Division of Medical Oncology, National Cancer Centre Singapore, Singapore; Duke-NUS Medical School, National University of Singapore, Singapore., Tan AC; Division of Medical Oncology, National Cancer Centre Singapore, Singapore; Duke-NUS Medical School, National University of Singapore, Singapore., Chan JWK; Division of Medical Oncology, National Cancer Centre Singapore, Singapore; Duke-NUS Medical School, National University of Singapore, Singapore., Teh YL; Division of Medical Oncology, National Cancer Centre Singapore, Singapore; Duke-NUS Medical School, National University of Singapore, Singapore., Tan WL; Division of Medical Oncology, National Cancer Centre Singapore, Singapore; Duke-NUS Medical School, National University of Singapore, Singapore., Ng QS; Division of Medical Oncology, National Cancer Centre Singapore, Singapore; Duke-NUS Medical School, National University of Singapore, Singapore., Ang MK; Division of Medical Oncology, National Cancer Centre Singapore, Singapore; Duke-NUS Medical School, National University of Singapore, Singapore., Kanesvaran R; Division of Medical Oncology, National Cancer Centre Singapore, Singapore; Duke-NUS Medical School, National University of Singapore, Singapore., Lim DWT; Division of Medical Oncology, National Cancer Centre Singapore, Singapore; Duke-NUS Medical School, National University of Singapore, Singapore., Tan DSW; Division of Medical Oncology, National Cancer Centre Singapore, Singapore; Duke-NUS Medical School, National University of Singapore, Singapore., Mok TSK; Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China., Li MSC; Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China.

Publikováno v: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2024 Jul; Vol. 193, pp. 107856. Date of Electronic Publication: 2024 Jun 15.